Mixed
Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.
You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.
Despite the lack of trials with blood pressure as a primary endpoint, current evidence supports their use in selected high-risk populations and suggests an emerging role in future guideline recommendations.
Why this rating
Based on the authors' analysis of current guidelines and trial designs.
Source
Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?
Dominik Kylies et al. · Current Hypertension Reports · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →